[EN] NOVEL COMPOUNDS FOR MODULATION OF ROR-GAMMA ACTIVITY<br/>[FR] NOUVEAUX COMPOSÉS POUR LA MODULATION DE L'ACTIVITÉ ROR-GAMMA
申请人:BIOGEN IDEC INC
公开号:WO2014028669A1
公开(公告)日:2014-02-20
The present invention relates to aryl sulfones and related compounds that are modulators of ROR-gamma receptors. The invention also provides pharmaceutical compositions comprising these modulators, and methods of modulating ROR-gamma receptors using them. Also provided are methods of using aryl sulfones and related compounds as modulators of ROR-gamma to treat ROR-gamma mediated diseases.
The design and preparation of metabolically protected new arylpiperazine 5-HT1A ligands
作者:Manish Tandon、Mary-Margaret O'Donnell、Alex Porte、David Vensel、Donglai Yang、Rocio Palma、Alan Beresford、Mark A. Ashwell
DOI:10.1016/j.bmcl.2004.01.045
日期:2004.4
New arylpiperazines related to buspirone, gepirone and NAN-190 were designed and screened in silico for their 5-HT1A affinity and potential sites of metabolism by human cytochrome P450 (CYP3A4). Modifications to these structures were assessed in silico for their influence on both 5HT(1A) affinity and metabolism. Selected new molecules were synthesized and purified in a parallel chemistry approach to determine structure activity relationships (SARs). The resulting molecules were assessed in vitro for their 5HT(1A) affinity and half-life in a heterologously expressed human CYP3A4 assay. Molecular features responsible for 5-HT1A affinity and CYP3A4 stability are described. (C) 2004 Elsevier Ltd. All rights reserved.